USBC, Inc.
Close on Oct 19, 2026
- Market cap
- $170.01M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2024 Ended Dec 31, 2023 | Feb 14, 2024 | After market close | – | $-0.04 | – |
| Q3 FY2023 Ended Jun 30, 2023 | Aug 18, 2023 | After market close | – | $-0.07 | – |
Press releases
Announcements USBC filed with the SEC
USBC Completes Divestiture of Legacy Sensor Technology Business
Material agreement · New financial obligation · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
USBC Regains Full NYSE American Compliance
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
USBC Executes Definitive Agreement with Uphold and Vast Bank to Advance Tokenized Bank Deposit Initiative
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
USBC Announces Completion of Corporate Name and Ticker Change Following Strategic Acquisition
Executive or director change · Other events · EX-99.1 to Form 8-K
Greg Kidd & Know Labs Announce Closing of $125M Strategic Acquisition
Material agreement · Agreement terminated · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Risks Related to Ownership of our Common Stock
Material agreement · Agreement terminated · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Greg Kidd to Acquire Controlling Interest in Know Labs and Introduce Bitcoin Treasury Strategy
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs Announces NYSE Removal of Trading Suspension
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs Announces Approval to Begin Trading on the OTCQB Market
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Know Labs Announces Cancellation of Special Meeting of Stockholders
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Know Labs Announces Reverse Stock Split Effective February 19 2025
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs Responds to NYSE Commencement of Proceedings to Delist
Listing notice · Other events · EX-99.1 to Form 8-K
Know Labs Launches Know Labs Technology Licensing (KTL)
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs, Inc. Announces $300K Registered Direct Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs, Inc. Announces NYSE American Acceptance of Plan to Regain Compliance
Listing notice · Other events · EX-99.1 to Form 8-K
Know Labs Announces Notification of Noncompliance with Additional NYSE American
Listing notice · Other events · EX-99.1 to Form 8-K
Know Labs, Inc. Announces $1.655 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs, Inc. Announces Pricing of $3.445 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs, Inc. Announces Closing of $3.445 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Know Labs Publishes Clinical Results in Leading Diabetes Journal
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs Secures U.S. $12 Million Funding for Company’s Further Execution
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs, Inc. Reports First Quarter FY2024 Results
Results of operations · EX-99.1 to Form 8-K
Know Labs Expands Medical and Scientific Advisory Board
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs Expands Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs Presents at Third Annual Bernstein CGM Disruptors Conference,
Regulation FD disclosure · EX-99.2 to Form 8-K
Know Labs, Inc. Announces Pricing of $7 Million Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs, Inc. Reports Third Quarter FY2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fiscal Year 2023 Third Quarter Earnings Conference Call
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Know Labs Demonstrates Improved Accuracy of Machine Learning Model for
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs’ Non-Invasive Glucose Monitoring Technology Shows Improved Accuracy
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs Study Validates Technical Feasibility of its Novel Sensor for
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED APRIL 21, 2023
Regulation FD disclosure · EX-99 to Form 8-K
Know Labs Forms New Scientific Advisory Board,
Regulation FD disclosure · EX-99.1 to Form 8-K
Know Labs Provides Update on Strategic Partners Engaged in Data Science, Product Engineering and Regulatory Affairs to Accelerate Progress Toward FDA Application
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JANUARY 4, 2023
Other events · EX-99 to Form 8-K